Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 16 2014
Print

Financial Report: Emergent BioSolutions



Published August 8, 2014
Related Searches: contractpharma.com contractpharma Development Biopharma
Emergent BioSolutions

2Q Revenues: $110.3 million (+34%)

2Q Earnings: $5.0 million (+51%)

YTD Revenues: $164.2 million (+31%)

YTD Loss: $15.2 million (earnings were $2.4 million YTD13)

Comments: This was the first full quarter of combined operations with Cangene.Product sales were $78.3 million, up 19%. Revenue from BioThrax was $67.5 million in the quarter, up 3%. Contract manufacturing revenue was $9.2 million in the quarter. R&D expenses were $37.4 million, up 23% primarily due to higher contract service costs, and includes increased technology and development expenses in both the Biodefense and Biosciences divisions.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On